Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications.

This multi-institutional real-world study evaluated the incidence of intraocular inflammation (IOI) following faricimab treatment across major retinal diseases. The study reviewed records of adults treated with faricimab between January 2022 and April 2025 and classified them into four disease cohorts: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and polypoidal choroidal vasculopathy (PCV). Patients with a recent history of IOI were excluded. In total, 7784 patients were analyzed, including 4085 with nAMD, 1456 with DME, 1057 with RVO, and 1166 with PCV. Mean ages varied by disease group, ranging from 65.5 years in DME to 75.6 years in nAMD, and more than half of all patients had prior intravitreal anti-VEGF therapy. Within 180 days of treatment initiation, the incidence of new-onset IOI was 0.54% with nAMD, 1.24% with DME, 1.23% with RVO, and 1.03% with PCV. Overall, IOI risk ranged from approximately 0.5 to 1.2%, with higher rates observed among patients with DME and RVO. These findings highlight the importance of ongoing pharmacovigilance as newer retinal therapeutics enter clinical practice, and they provide timely evidence to support safety monitoring in real-world ophthalmology settings.